Hepatocyte growth factor triggers a complex biological program leading to invasive cell growth by activating the c-Met receptor tyrosine kinase. Following activation, Met signaling is elicited via its interactions with SH2-containing proteins, or via the phosphorylation of the docking protein Gab1, and the subsequent interaction of Gab1 with additional SH2-containing eector molecules. We have previously shown that the interaction between phosphorylated Gab1 and the adaptor protein Crk mediates activation of the JNK pathway downstream of Met. We report here that c-Cbl, which is a Gab1-like docking protein, also becomes tyrosine-phosphorylated in response to Met activation and serves as a docking molecule for various SH2-containing molecules, including Crk. We further show that Cbl is similarly capable of enhancing Met-induced JNK activation, and several lines of experimentation suggests that it does so by interacting with Crk. We also show that both Cbl and Gab1 enhance Met-induced activation of another MAP kinase cascade, the ERK pathway, in a Crk-independent manner. Taken together, our studies demonstrate a previously unidenti®ed functional role for Cbl in Met signaling and suggest that Met utilizes at least two docking proteins, Gab1 and Cbl, to activate downstream signaling pathways. Oncogene (2000) 19, 4058 ± 4065.
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Keywords: kinase; oncogenesis; signal transduction; tyrosine phosphorylation Hepatocyte growth factor/scatter factor (HGF/SF) triggers a complex biological program leading to invasive cell growth by activating its high-anity receptor, the c-Met transmembrane tyrosine kinase (for reviews see Bardelli et al., 1997b; Vande Woude et al., 1997) . In addition to mediating biological responses in normal cells, Met-HGF/SF signaling has been implicated in the generation and spread of tumors (Jeers et al., 1996) . Most notably, missense mutations that deregulate the enzymatic activity of Met have been found to be associated with human papillary renal carcinomas (Fischer et al., 1998; Jeers et al., 1997a; Schmidt et al., 1997; Zhuang et al., 1998) . Consistent with these ®ndings, Met was originally identi®ed as an oncogene, Tpr/Met, which codes for a constitutively activated Met kinase possessing transforming activity (Cooper et al., 1984; Park et al., 1986; Rodrigues and Park, 1993) .
The cytoplasmic domain of Met contains two autophosphorylation tyrosine residues, tyrosines 1349 and 1356, which form a multi-substrate binding site for several SH2-domain-containing cytoplasmic eectors and are thought to be crucial for Met-induced biological signaling (Ponzetto et al., 1994; Weidner et al., 1995; Zhu et al., 1994) . In addition to the numerous SH2-containing molecules, the 110-kDa docking protein Gab1 also interacts with the activated Met receptor, either directly or indirectly via the adaptor protein Grb2 Nguyen et al., 1997; Weidner et al., 1996) . Gab1, which becomes tyrosine phosphorylated upon Met stimulation, contains multiple domains capable of binding to signaling molecules, such as Grb2, the p85 subunit of PI 3-kinase, phospholipase C-g and SHP2 (see Bardelli et al., 1997b) . Together, these data support a model in which Met signaling could be elicited directly via its interactions with SH2-containing proteins or establishment of a Met/(Grb2)/Gab1 complex and the subsequent interaction of Gab1 with additional SH2-containing eector molecules.
Among the diverse biochemical pathways triggered by Met is the stimulation of mitogen-activated protein kinases (MAPK), including c-Jun N-terminal kinases (JNK). Importantly, it has been shown that JNK activation is essential for cellular transformation and induction of soft agar growth by Tpr/Met (Rodrigues et al., 1997) . Recent ®ndings in our laboratory have established that the SH2-SH3-domain containing adaptor protein c-Crk is a component in connecting various cellular stimuli to JNK activation (Dol® et al., 1998) . In a previous work, we set forth to determine whether a connection between the Met and the Crk pathways might play a role in Met-induced JNK activation and cellular transformation. We found that tyrosine-phosphorylated Gab1 serves as a functional docking site for the SH2-domain of Crk, the dominantnegative forms of Crk block Met-induced JNK activation and that Gab1-Crk complex formation correlates with stimulation of the JNK pathway by Met (Garcia-Guzman et al., 1999) . We report here that c-Cbl, which is a proto-oncogene product and a Gab1-like docking protein, is also a component in Met signaling pathways. Upon Met-induced phosphorylation, Cbl interacts with Crk and other SH2-domain containing molecules, connecting Met to the JNK pathway in a Crk-dependent manner. We also show that both Cbl and Gab1 enhance Met-induced activation of another MAP kinase cascade, the ERK pathway, in a Crk-independent manner. Collectively, our studies described below demonstrate a heretofore unidenti®ed functional role for the docking protein Cbl in Met signaling pathways.
A previous report by Fixman et al. (1997) has demonstrated that the 120 kDa c-Cbl protein becomes tyrosine phosphorylated in Tpr/Met-transformed cells. To further characterize the potential role of Cbl in Met signaling, we studied in more detail the phosphorylation status of Cbl in cells in which Met signaling has been activated either by HGF/SF stimulation or by a transient Tpr/Met transfection. Unless otherwise indicated, the results shown are those obtained with HeLa cells; similar results were obtained in Cos-7 and NIH3T3 cells. As shown in Figure 1a , Cbl readily becomes phosphorylated on tyrosine in HGF/SFtreated cells in a dose-and time-dependent manner. Phosphorylation of Cbl is induced rapidly, within minutes of receptor engagement, and it closely parallels the autophosphorylation status of the Met receptor. Further, Cbl phosphorylation occurs at low (20 ± Figure 1 Met kinase activity induces Cbl tyrosine phosphorylation and association with SH2-signaling molecules. (a) HeLa cells were treated with various concentrations of HGF/SF for the indicated times. Cell lysates (50 mM HEPES pH=7.9, 1% Triton X-100, 10% glycerol, 150 mM NaCl, 1 mM EGTA, 200 mM Na 3 VO 4 , 50 mM NaF, 1.5 mM MgCl 2 , 10 mg/ml leupeptin, 0.1 U/ml aprotinin and 1 mM phenylmethylsulfonyl¯uoride) containing equal amounts of protein were subjected to immunoprecipitation using antibodies against Cbl (upper panels, Santa Cruz Biotechnology #sc-170-G) or Met (lower panels, Santa Cruz Biotechnology #sc-161) and the immunoprecipitates were analysed by immunoblotting with anti-phosphotyrosine (anti-PY, PY20 : HRPO, Transduction Laboratories #P11625), anti-Cbl or anti-Met antibodies (ascites from mouse monoclonal hybridoma raised against the C-terminal portion of Met, provided by Dr G Vande Woude) as indicated. (b) HeLa cells were transiently transfected with mammalian expression vectors coding for Tpr/Met wild type (`WT') (obtained from Dr G Vande Woude), Tpr/Met Y482F-Y489F (`YY') or Tpr/Met K243A (`KD') (Garcia-Guzman et al., 1999) . Lysates containing equal amounts of protein were subjected to immunoprecipitation using anti-Cbl antibodies (upper and middle panels) and analysed by immunoblotting with antiphosphotyrosine (upper panel) or anti-Cbl antibodies (middle panel). Total cell lysates were analysed by immunoblotting with anti-Met antibodies to con®rm equal expression levels of the various Tpr/Met constructs. (c) Lysates containing equal amounts of protein from HeLa cells stimulated (+) or not (7) with 50 ng/ml of HGF/SF for 15 min were incubated with the indicated GSTfusion proteins coupled to glutathione agarose as described in (Vuori et al., 1996) . The precipitates were analysed by immunoblotting with anti-Cbl antibodies. The protein samples used for the in vitro association experiments contained equal amounts of Cbl, as demonstrated by anti-Cbl immunoblotting of total cell lysates (right panel). (d) HGF/SF stimulation induces association of Cbl with the adaptor protein Crk. HeLa cells were treated (+) or not (7) with 50 ng/ml of HGF/SF for 15 min and lysates containing equal amounts of protein were immunoprecipitated with anti-Cbl antibodies or incubated with protein Asepharose in the absence of the primary antibody (`prot A', negative control). The presence of Crk in the Cbl immunecomplexes was analysed by immunoblotting with anti-Crk antibodies (left panel). The amount of Crk present in the total protein lysates in the nonstimulated (7) and stimulated (+) cells was shown to be equal by immunoblot analysis (right panel) 100 ng/ml) ligand concentrations; these same concentrations have been shown to induce activation of biologically important signaling events downstream of Met (Boccaccio et al., 1998; Ponzetto et al., 1994) . As shown by Fixman et al. (1997) , Cbl also becomes tyrosine phosphorylated in cells expressing the oncogenic Tpr/Met (Figure 1b) . Interestingly, previous reports have established a correlation between Tpr/ Met-induced transformation and Gab1 phosphorylation; it has been demonstrated that both the kinase activity and the integrity of the multi-substrate binding site are required for cellular transformation and Gab1 phosphorylation by the Tpr/Met oncogene (Bardelli et al., 1997a; Fixman et al., 1997) . We ®nd here the same to be true for Tpr/Met-induced Cbl phosphorylation. As shown in Figure 1b , induction of Cbl phosphorylation is negligible in HeLa cells transfected with the kinase-dead form of Tpr/Met (`KD'), or with the form of Tpr/Met in which the tyrosine residues in the multisubstrate binding site have been mutated to phenylalanine residues (tyrosines 482 and 489 in Tpr/Met, YY'). Immunoblot analysis con®rmed that the Tpr/ Met variants were expressed at similar levels in the cells (Figure 1b ). Taken together, activation of Met signaling either by physiological levels of HGF/SF or by expression of the Tpr/Met oncogene results in enhanced tyrosine phosphorylation of Cbl. The characteristics of this phosphorylation are similar to those observed for Gab1, an established docking molecule in Met signaling events.
Cbl is known to become tyrosine phosphorylated in response to a number of cellular stimuli, including ligation of T-cell and B-cell receptors, Fc-receptors, integrins, receptors for GM-CSF, erythropoietin, thrombopoietin, interleukins -3 and -4 and prolactin, and stimulation of several receptor tyrosine kinases, such as receptors for PDGF, EGF, NGF, insulin and stem cell factor. As a result, Cbl binds to several SH2-domain containing molecules, such as Crk, the p85 subunit of PI 3-kinase and Src family tyrosine kinases (for original references, see Lupher et al., 1998; Miyake et al., 1997) . We ®nd that stimulation of cells with HGF/SF also enhances the interaction of Cbl with SH2-domain containing proteins. As shown in Figure  1c , Cbl readily interacts with the SH2-domains of Src and p85 in HGF/SF-stimulated HeLa cells, but not in unstimulated cells (Figure 1c) . HGF/SF stimulation also enhances the association of Cbl with the SH2-domain of Crk, while the tyrosine phosphorylationindependent interaction between Cbl and the SH3-domain of Grb2 remains unchanged upon HGF/SF stimulation; Cbl is known to interact with Grb2 in a constitutive manner by binding to the SH3-domain of Grb2 (for references, see Miyake et al., 1997) . As a control for speci®city, we found that the SH2-domains of PLC-g and Shc failed to interact with Cbl in both unstimulated and stimulated cells (Figure 1c) . The CblCrk interaction was con®rmed by coimmunoprecipitation experiments. As shown in Figure 1d , stimulation of HeLa cells with HGF/SF results in a signi®cant increase in the amount of c-Crk-I and c-Crk-II, the two cellular forms of c-Crk, associated with Cbl. These studies suggest that tyrosine-phosphorylated Cbl, similar to tyrosine-phosphorylated Gab1, may function as a docking molecule in Met signaling pathways and connect Met to SH2-containing eector molecules. c-Crk is an adaptor protein that is mainly composed of SH2-and SH3-domains (Feller et al., 1998; Matsuda and Kurata, 1996) . We have previously determined that Crk connects multiple cellular stimuli to the JNK pathway and that intact SH2-and SH3-domains in Crk are required for this function (Dol® et al., 1998) . In a previous report, we identi®ed tyrosine-phosphorylated Gab1 as a Crk-SH2-binding molecule in cells in which Met signaling had been activated. We also found that expression of Gab1 enhanced Met-induced JNK activation in a Crk-dependent manner (Garcia-Guzman et al., 1999) . To investigate whether the Metinduced Cbl-Crk interaction observed here might be of functional signi®cance in Met signaling pathways, we examined the ability of Cbl to modulate Met-induced JNK activity. As shown in Figure 2 , expression of Tpr/ Met in HeLa cells or stimulation of the cells with HGF/SF results in activation of the JNK kinase cascade as measured by a JNK kinase assay ( Figure  2a) or by a c-Jun transcriptional activity assay ( Figure  2b ). There appears to be good correlation between Met-induced JNK activation and Cbl phosphorylation: in a previous study, we found that HGF/SF stimulates JNK activation in a dose-dependent manner (GarciaGuzman et al., 1999) that closely parallels Cbl phosphorylation observed here ( Figure 1a) . Further, we demonstrated earlier that the kinase-dead form of Tpr/Met and the form of Tpr/Met in which the tyrosine residues in the multi-substrate binding site have been mutated to phenylalanine residues fail to activate JNK (Garcia-Guzman et al., 1999); these forms of Tpr/Met also fail to induce Cbl phosphorylation (Figure 1b) . Similar to our ®ndings with Gab1 (Garcia-Guzman et al., 1999), we ®nd here that exogenous expression of Cbl enhances Tpr/Met-and HGF/SF-induced JNK activation by about 3 ± 4-fold ( Figure 2) ; expression of Cbl in the absence of Met signaling had no eect on JNK activity (not shown). Two lines of experimentation suggest that this enhancement is mediated by the Cbl-Crk interaction. First, we found that expression of a c-Crk-I construct in which the SH2-domain has been inactivated by an arginine-to-valine mutation at amino acid 38 (Crk-R38V-mutant) eectively abolishes the enhancing eect of Cbl on Met-induced JNK activation (Figure 2a,b) . Previous studies by us and others have established that the Crk-R38V-mutant is a speci®c dominant-negative mutant in Crk signaling pathways and functionally dissociates tyrosine-phosphorylated Crk-SH2-binding proteins from the eector molecules that bind to the SH3-domain of Crk (Dol® et al., 1998; Garcia-Guzman et al., 1999; Klemke et al., 1998; Matsuda et al., 1992 Matsuda et al., , 1994 Tanaka et al., 1993 Tanaka et al., , 1995 . Second, we found that the capability of Cbl to enhance Met-induced JNK activation is signi®cantly reduced when the tyrosines at either position 700 or 774 in Cbl has been mutated to phenylalanine (Figure 2c ). An even more profoundly reduced eect is observed when a Cbl construct harboring mutations in both of the tyrosines was tested for its capability to enhance Met-induced JNK activation (Figure 2c) . No dierences in the expression levels among the various Cbl-constructs were observed (not shown). The sequences around the tyrosine residues 700 and 774 conform to the consensus SH2-binding site for Crk (Songyang et al., 1993) , and previous reports have established that these two tyrosines, when phosphorylated, mediate the interaction between Cbl and Crk (Andoniou et al., 1994; Reedquist et al., 1996; Sawasdikosol et al., 1996) . Taken together, our studies indicate that Cbl, similar to Gab1, is capable of enhancing Met-induced JNK activation in a Crk-dependent manner.
In order to gain further insight into the roles of Crk, Cbl and Gab1 in Met signaling pathways, we decided to study the capability of oncogenically activated Met to activate the JNK pathway and the potential roles of Crk, Cbl and Gab1 in mediating this eect. Met receptor harboring point mutations at sites 1213 and 1268 (Met L1213V/M1268T) is an example of an oncogenic Met mutant that was originally identi®ed in human papillary renal carcinoma (Schmidt et al., 1997) and later shown to possess constitutive kinase activity and transformation ability (Jeers et al., 1997a) . At present, relatively little is known about the molecular signaling mechanisms downstream of these oncogenic Met receptors, although some dierences between the signaling strategies employed by these receptors and by the oncogenic Tpr/Met receptor may exist (Jeers et al., 1998) . We demonstrate here that similar to Tpr/ Met expression, expression of Met (L1213V/M1268T; Met LM in the ®gures) results in a robust activation of the JNK pathway in HeLa cells (Figure 3a) . Expression of Met (L1213V/M1268T) also signi®cantly enhances tyrosine phosphorylation of both Cbl and Gab1 (Figure 3a , lower panels). As shown in Figure 3b , activation of JNK and phosphorylation of Cbl in Figure 2 (a) Activation of JNK by Met kinase is enhanced by expression of Cbl and blocked by a dominant-negative Crk construct. HeLa cells were transiently transfected with plasmids (5 mg/dish each) encoding wild-type Tpr/Met (`Tpr/Met'), Cbl, dominant-negative Crk-R38V or Flag-tagged JNK (`JNK') as indicated, and subjected to a JNK immunecomplex kinase assay using GST/c-jun (1 ± 79) (`GST/c-jun') as a substrate; constructs for Tpr/Met, Crk-38V and Flag-tagged JNK, transfections and kinase assay have been described in (Garcia-Guzman et al., 1999). The total amount of DNA used for transfections to study in vitro kinase activity was maintained constant by using a neutral mammalian expression vector (pcDNA3 plasmid, Stratagene). Wild-type Cbl in a pJZenNeo-vector was obtained from Dr WY Langdon. Expression of the transfected proteins was assessed by immunoblotting with anti-Met, anti-Cbl, anti-Crk (Transduction Laboratories #C12620) and anti-Flag antibodies (anti-FLAG M2 mAb, Eastman Kodak). The upper graph shows the normalized median values of three independent experiments with the standard deviation. Where indicated, the cells were stimulated with 50 ng/ml of HFG/SF for 15 min prior to cell lysis. (b) Met-induced transcriptional activation of c-Jun is enhanced by Cbl expression in a Crk-dependent manner. HeLa cells were transfected with pFR-Luc (1 mg) and pFA-c-Jun (1 ± 223) (`Gal4/Jun', 50 ng) plasmids (PathDetect Reporting System, Stratagene) and the expression vectors for Tpr/ Met, Cbl or Crk-R38V at 1 mg/dish each as indicated. Gal4-c-Jun transcriptional activity was determined by measuring activity levels of the luciferase reporter gene as described in (Garcia-Guzman et al., 1999) . The total amount of DNA used for transfections to study transcriptional control of luciferase was maintained constant by using a neutral mammalian expression vector (pcDNA3). Transcriptional luciferase assays in this manuscript are indicated as RLU (relative luciferase unit) with the standard deviation (n=3), and were normalized for cotransfected (50 ng Met signaling induced by HGF/SF stimulation or by Tpr/Met expression is known to activate two parallel MAP kinase pathways, the JNK pathway and the ERK pathway (Rodrigues et al., 1997) . Our results depicted in Figure 3 demonstrate that activation of Met signaling by expression of Met (L1213V/M1268T) activates the JNK-arm of the MAP kinase pathway. As Figure 2 (upper panels show the normalized median values of three independent experiments with the standard deviation). In parallel, cell lysates containing equal amounts of protein from HeLa cells that had been transfected with plasmids coding for wildtype Met or oncogenic Met (L1213V/M1268T) were subjected to immunoprecipitation analysis by anti-Cbl and anti-Gab1 (Upstate Biotechnology #06-5790) antibodies followed by immunoblotting using anti-phosphotyrosine antibodies (lower panels). The amounts of Cbl in the immunoprecipitates and the Met proteins in the total cell lysates were determined by immunoblotting using the speci®c antibodies (lower panels). (b) The activation of JNK by Met (L1213V/M1268T) correlates with the phosphotyrosine levels of Cbl in a dose-dependent manner. JNK immunecomplex kinase assays were performed as in (a) but using increasing amounts of the plasmid encoding the mutant Met (L1213V/M1268T) for transfections; the total amount of DNA used for the transfections was equalized by using a neutral mammalian expression vector, pCDNA3 (upper panel). In parallel experiments, tyrosine phosphorylation of Cbl was examined in cells harboring the various amounts of Met (L1213V/M1268T). The expression levels of Met (L1213V/M1268T) in the various samples were examined by anti-Met immunoblotting of the total cell lysates (lower panels). (c and d) Induction of JNK activation by Met (L1213V/M1268T) is enhanced by co-expression of Cbl (c) and Gab1 (d) and blocked by the dominant-negative Crk-mutant. HeLa cells were transiently transfected by the indicated plasmids, and a JNK immunecomplex kinase assay was carried out as above (upper panels). Immunoblot analysis of the expressed proteins (middle panels) were performed as above; expression levels of the HA-tagged Gab1 (obtained from Drs M Holgado-Madruga and A Wong) were assessed by immunoblotting total cell lysates using anti-HA antibodies (Santa Cruz Biotechnology #sc-805). Similar ®ndings were obtained in experiments in which the eects of Met (L1213V/M1268T), Cbl, Gab1 and Crk-R38V on the JNK pathway were analysed in a c-Jun transcriptional assay (lower panels in c and d) shown in Figure 4 , expression of Met (L1213V/ M1268T) also results in induction of ERK activation as measured by an ERK kinase assay (Figure 4a,c) or by an Elk transcriptional activity assay (Figure 4b ). It has been reported that overexpression of Gab1 in epithelial cells leads to phosphorylation of ERK1 and ERK2 (Weidner et al., 1996) , suggesting that Gab1 may be mediating the eects of Met on the ERK kinase cascade. Along these lines, we ®nd that expression of Gab1 enhances Met (L1213V/M1268T)-induced ERK activation (Figure 4c) . Similarly, we ®nd that expression of Cbl also enhances activation of the ERK pathway downstream of Met (L1213V/M1268T) by about 2 ± 3-fold (Figure 4a,b) . Notably, the eects of Cbl and Gab1 on ERK activation were not aected by a concomitant expression of the dominant-negative Crk-R38V construct (Figure 4 ). Taken together, our studies demonstrate that the docking proteins Gab1 and Cbl modulate Met-induced activation of MAP kinase pathways; our ®ndings described here and earlier (Garcia-Guzman et al., 1999) support a role for Gab1-Crk and Cbl-Crk complex formation in the activation of the JNK kinase cascade, while Metinduced activation appears to take place in a Crkindependent manner. Both Gab1 and Cbl interact with Grb2, an adaptor protein that couples activated receptor tyrosine kinases to SOS, promoting Ras/Raf/ ERK activation (Donovan et al., 1994; Fixman et al., 1995; Fukazawa et al., 1995; Meisner et al., 1995; Odai et al., 1995; Ponzetto et al., 1996; Zhu et al., 1994) . It was reported recently, however, that dominant-negative forms of Grb2 fail to inhibit Met-induced ERK activation (Rodrigues et al., 1997) , and the downstream pathways leading to ERK kinase cascade activation remain unknown at present.
Our ®ndings described above identify a novel functional role for the docking protein Cbl in Met signaling. Similar to another docking protein, Gab1, Cbl associates with the adaptor protein Crk and enhances Met-induced JNK activation in a Crkdependent manner. We have previously established that Crk-mediated JNK activation takes place via activation of the small GTP-binding protein Rac, which in turn occurs through the Crk SH3-binding proteins, such as C3G, Sos or DOCK180 (Dol® et al., 1998) . Recently, Scaife and Langdon (2000) have reported that the Cbl-Crk interaction results in Rac activation, and our studies (unpublished data) agree with these ®ndings. Also, we have found that dominant-negative Rac blocks the enhancement of JNK activation by Cbl (not shown). Rodrigues et al. (1997) in turn have reported that a dominant-negative mutant of Rac eciently blocks Tpr/Met-induced JNK activation and transformation. Taken together, these data suggest a linear pathway from Gab1-Crk and CblCrk to Rac activation that ultimately stimulates the ) is enhanced by co-expression of Cbl. HeLa cells were transfected with expression vectors encoding the indicated proteins (5 mg/dish each) and analysed by an ERK immunecomplex kinase assay using myelin basic protein (MBP) as a substrate; the HA-tagged ERK construct and the kinase assay protocol have been described in (Garcia-Guzman et al., 1999) . The bar graph represents the mean with the standard deviation. Expression levels of the proteins were determined by immunoblotting analysis as above (lower panels). In (b) Elk-mediated transcriptional activity was determined by a luciferase assay (PathDetect Reporter System, Stratagene) in cells that had been transfected with the indicated plasmids as described in (Garcia-Guzman et al., 1999) . (c) Activation of ERK by Met (L1213V/M1268T) is enhanced by co-expression of Gab1. HeLa cells were transfected with the indicated plasmids (5 mg/dish each) and an ERK immunecomplex kinase assay in the transfected cells was carried out as in (a). The expression levels of the transfected proteins were assessed as above JNK kinase and controls biological events downstream of Met. Along these lines, Feller and coworkers have recently reported on the importance of Crk signaling complexes in connecting Met to the small GTPase Rap1 (Sakkab et al., 2000) . The relative signi®cance of Gab1 and Cbl in Met signaling pathways needs to be addressed e.g. by utilizing cell lines generated from knockout mice de®cient in Gab1-and Cbl-family signaling proteins.
It remains to be seen whether Gab1 and Cbl might have a similar function in other signaling pathways. It is interesting to note that several common upstream stimuli appear to regulate both Gab1 and Cbl phosphorylation; in addition to c-Met stimulation, these stimuli activate other receptor tyrosine kinases such as EGF receptor, insulin receptor, TrkA receptor, receptors for several cytokines such as interleukins and interferons, thrombopoietin and stem cell factor, as well as T-and B-cell receptors (for original references, see Holgado-Madruga et al., 1996; Lupher et al., 1998; Miyake et al., 1997; Nishida et al., 1999) . Relatively little is known about the functional signi®cance of Gab1 in these other pathways. It has been reported that Gab1 mediates PI 3-kinase activation downstream of NGF signaling, while in the cytokine signaling pathways, Gab1 appears to link the receptors to the ERK pathway Takahashi-Tezuka et al., 1998) . Cbl in turn has been shown to be an important downstream component in Src signaling pathways in osteoclasts (Tanaka et al., 1996) . In addition, Cbl has been demonstrated to enhance PI 3-kinase activity and proliferation of cells in the presence of IL-4 and G-CSF (Grishin et al., 2000; Ueno et al., 1998) . Similarly, Cbl has been shown to regulate integrin-mediated cell adhesion, spreading and migration in a PI 3-kinase-dependent manner (Feshchenko et al., 1999; Meng and Lowell, 1998; Zell et al., 1998) .
More recently, a wealth of information has accumulated on the role of Cbl as a negative regulator of receptor tyrosine kinase signaling. Thus, it has been demonstrated that Cbl positively regulates ubiquitination of receptors for EGF, PDGF and CSF-1 in a manner that depends on its variant SH2-domain and a RING ®nger domain; Cbl binds to the tyrosinephosphorylated receptor via its SH2-domain, and recruits and allosterically activates an E2-ubiquitinconjugating enzyme through its RING domain (Joazeiro et al., 1999; Lee et al., 1999; Levkowitz et al., 1998 Levkowitz et al., , 1999 Miyake et al., 1998; Waterman et al., 1999; Yokouchi et al., 1999) . Ubiquitination of the receptor tyrosine kinases in turn terminates signaling by marking active receptors for degradation via the proteasome pathway (for a review, see Ciechanover, 1998) . Consequently, expression of Cbl results in inhibition of receptor tyrosine kinase activation and growth factor-mediated cell proliferation. Somewhat unexpectedly, however, expression of Cbl has not been shown to signi®cantly modulate e.g. ERK signaling downstream of receptor tyrosine kinases. Thus, Langdon and coworkers have found that expression of Cbl inhibits autophosphorylation of EGFR in response to EGF stimulation, yet EGF-induced ERK kinase activity remains unaected in these cells (Bowtell and Langdon, 1995; Thien and Langdon, 1997) . Similar ®ndings have been obtained by Ueno et al. (1997) and by us (unpublished data). Collectively, these results suggest that at least in vitro, c-Cbl has no eect or only a marginal eect on EGF-induced ERK and JNK activation, while it functions as a positive regulator of Met-induced MAP kinase activation. In contrast, the c-Cbl homologs cbl-b and cbl-3 have been found to function as negative regulators of ERK and JNK pathways downstream of EGFR (Bustelo et al., 1997; Ettenberg et al., 1999; Keane et al., 1999) ; their role in e.g. Met signaling remains unknown. We have not explicitly examined the potential role of c-Cbl in regulating protein levels or tyrosine kinase activity of Met. Interestingly, however, it has been reported that degradation of Met takes place via the ubiquitinproteasome pathway (Jeers et al., 1997b) . The possibility that Cbl might function both as a positive and negative regulator to control intracellular signaling cascades downstream of Met is intriguing and warrants further study.
